Cantor Fitzgerald Research Analysts Lower Earnings Estimates for Fennec Pharmaceuticals Inc. (TSE:FRX)

Fennec Pharmaceuticals Inc. (TSE:FRXGet Rating) – Stock analysts at Cantor Fitzgerald decreased their FY2023 earnings per share estimates for shares of Fennec Pharmaceuticals in a note issued to investors on Monday, May 15th. Cantor Fitzgerald analyst C. Duncan now expects that the biopharmaceutical company will post earnings per share of ($0.69) for the year, down from their prior estimate of ($0.63). The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.08 per share.

Fennec Pharmaceuticals (TSE:FRXGet Rating) last announced its quarterly earnings results on Thursday, March 30th. The biopharmaceutical company reported C($0.35) EPS for the quarter, missing analysts’ consensus estimates of C($0.33) by C($0.02).

Fennec Pharmaceuticals Price Performance

Shares of Fennec Pharmaceuticals stock opened at C$10.14 on Wednesday. The company has a debt-to-equity ratio of 881.09, a current ratio of 5.80 and a quick ratio of 10.17. The business’s 50 day simple moving average is C$11.05 and its two-hundred day simple moving average is C$12.17. The stock has a market capitalization of C$267.90 million, a P/E ratio of -8.52 and a beta of 0.16. Fennec Pharmaceuticals has a one year low of C$6.70 and a one year high of C$14.41.

About Fennec Pharmaceuticals

(Get Rating)

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014.

Read More

Earnings History and Estimates for Fennec Pharmaceuticals (TSE:FRX)

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with's FREE daily email newsletter.